Cargando…

The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study

Detalles Bibliográficos
Autores principales:	Badawy, Sherif M., Kattamis, Antonis, Ezzat, Hatoon, Deschamps, Benoît, Sicard, Eric, Fradette, Caroline, Zhao, Feng, Tricta, Fernando, Chung Tsang, Yu, Sheth, Sujit, Piga, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letters to the Editor‐online only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303221/ https://www.ncbi.nlm.nih.gov/pubmed/34931307 http://dx.doi.org/10.1111/bjh.17999

Ejemplares similares

PB2231: RATIONALE FOR THE USE OF COMBINATION CHELATION THERAPY IN PATIENTS WITH THALASSEMIA SYNDROMES OR SICKLE CELL ANEMIA: A SYSTEMATIC LITERATURE REVIEW
por: Kattamis, A., et al.
Publicado: (2022)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW
por: Piga, A., et al.
Publicado: (2022)

Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years
por: Elalfy, Mohsen S., et al.
Publicado: (2022)

Chelation Therapy with Oral Solution of Deferiprone in Transfusional Iron-Overloaded Children with Hemoglobinopathies
por: Makis, Alexandros, et al.
Publicado: (2013)

Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study
por: Kwiatkowski, Janet L., et al.
Publicado: (2022)

Effects of renal impairment on the pharmacokinetics of orally administered deferiprone
por: Fradette, Caroline, et al.
Publicado: (2016)

PB2565: TRANSFUSIONAL IRON OVERLOAD AND ASSOCIATED COMPLICATIONS IN HEMATOLOGY DISORDERS PATIENTS
por: Romanenko, Nikolay, et al.
Publicado: (2023)

P1442: PRACTICE-BASED EVIDENCE: LONG-TERM SAFETY COHORT OF DEFERIPRONE IN PATIENTS WITH SICKLE CELL DISEASE FROM THE US REGISTRY
por: Badawy, Sherif, et al.
Publicado: (2023)

The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease
por: Soulières, Denis, et al.
Publicado: (2022)

PB2519: THE EFFECT OF PREVENTIVE HEALTH PROGRAM ON KNOWLEDGE AND SCREENING OF SICKLE CELL DISEASE AMONG HIGH SCHOOL AGED GROUP – THE SAUDI ARABIA EXPERIENCE
por: Ezzat, Hatoon
Publicado: (2023)

Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
por: Bentley, Anthony, et al.
Publicado: (2013)

S120: RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF DEFERIPRONE: SUBGROUP ANALYSIS OF PEDIATRIC PATIENTS IN IRON-OVERLOADED PATIENTS WITH SICKLE CELL DISEASE AND OTHER ANEMIAS
por: Inusa, B, et al.
Publicado: (2022)

Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
por: Bentley, Anthony, et al.
Publicado: (2013)

S123: SAFETY AND EFFICACY OF EARLY-START DEFERIPRONE IN INFANTS AND YOUNG CHILDREN WITH BETA-THALASSEMIA (START STUDY)
por: Elalfy, M, et al.
Publicado: (2022)

S115: LONG-TERM EFFICACY AND SAFETY OF DEFERIPRONE FOR PATIENTS WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
por: Inusa, B, et al.
Publicado: (2022)

P1558: EARLY-START DEFERIPRONE IN INFANTS/YOUNG CHILDREN WITH TRANSFUSION-DEPENDENT BETA THALASSEMIA: EVIDENCE FOR IRON SHUTTLING TO TRANSFERRIN—RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (START)
por: Tricta, F., et al.
Publicado: (2022)

Deferiprone‐induced agranulocytosis: 20 years of clinical observations
por: Tricta, Fernando, et al.
Publicado: (2016)

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
por: Smith, Gillian C, et al.
Publicado: (2011)

Treating thalassemia major-related iron overload: the role of deferiprone
por: Berdoukas, Vasilios, et al.
Publicado: (2012)

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab
por: van Rhee, Frits, et al.
Publicado: (2020)

Management of transfusional iron overload – differential properties and efficacy of iron chelating agents
por: Kwiatkowski, Janet L
Publicado: (2011)

The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes
por: Petrou, Emmanouil, et al.
Publicado: (2015)

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
por: Gattermann, Norbert
Publicado: (2008)

The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia
por: Kontoghiorghes, George J., et al.
Publicado: (2020)

Medicina transfusional
Publicado: (2010)

Medicina transfusional
Publicado: (2006)

Medicina transfusional

PB2520: NEWBORN SCREENING PROGRAM IN SAUDI ARABIA FOR EARLY DETECTION OF HEMOGLOBINOPATHIES AND G6PD
por: Ezzat, Hatoon, et al.
Publicado: (2023)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review
por: Salem, Ahmed, et al.
Publicado: (2023)

The Medical Research Council (UK)/Uganda Virus Research Institute Uganda Research Unit on AIDS – ‘25 years of research through partnerships’
por: Kaleebu, P, et al.
Publicado: (2015)

Cognitive Function of Children and Adolescents With Congenital Adrenal Hyperplasia: Importance of Early Diagnosis
por: Messina, Valeria, et al.
Publicado: (2020)

Changes in orthodontics during the COVID-19 pandemic that have come to stay
por: García-Camba, Pablo, et al.
Publicado: (2020)

COVID-19: What do we know?
por: Marshall, Steve, et al.
Publicado: (2020)

Bridging worldviews: Toward a common model of leadership across the health professions
por: Garman, Andrew N., et al.
Publicado: (2020)

IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction
por: Joustra, Sjoerd D, et al.
Publicado: (2019)

Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma
por: Chortis, Vasileios, et al.
Publicado: (2019)

Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer
por: van Velsen, Evert F S, et al.
Publicado: (2019)

Bone Mineral Density After Transitioning From Denosumab to Alendronate
por: Kendler, David, et al.
Publicado: (2019)

Divergent Metastatic Patterns Between Subtypes of Thyroid Carcinoma Results From the Nationwide Dutch Pathology Registry
por: Hugen, Niek, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gjgnoc5grda93svuoseqtagtoc